Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1996 Oct 1;93(20):10685–10690. doi: 10.1073/pnas.93.20.10685

Conformational change and enhanced stabilization of the vitamin D receptor by the 1,25-dihydroxyvitamin D3 analog KH1060.

G C van den Bemd 1, H A Pols 1, J C Birkenhäger 1, J P van Leeuwen 1
PMCID: PMC38215  PMID: 8855240

Abstract

The 1,25-dihydroxyvitamin D3 [1,25-(OH)2vitamin D3] analog KH1060 exerts very potent effects on cell proliferation and cell differentiation via the vitamin D receptor (VDR). However, the activities of KH1060 are not associated with an increased affinity for the VDR. We now show that increased stabilization of the VDR-KH1060 complex could be an explanation for its high potencies. VDR half-life studies performed with cycloheximide-translational blocked rat osteoblast-like ROS 17/2.8 cells demonstrated that, in the absence of ligand, VDR levels rapidly decreased. After 2 hr, less than 10% of the initial VDR level could be measured. In the presence of 1,25-(OH)2vitamin D3, the VDR half-life was 15 hr. After 24 hr. less than 20% of the initial VDR content was detectable, whereas, at this time-point, when the cells were incubated with KH1060 80% of the VDR was still present. Differences in 1,25-(OH)2vitamin D3- and KH1060-induced conformational changes of the VDR could underlie the increased VDR stability. As assessed by limited proteolytic digestion analysis, both 1,25-(OH)2vitamin D3 and KH1060 caused a specific conformational change of the VDR. Compared with 1,25-(OH)2vitamin D3, KH1060 induced a conformational change that led to a far more dramatic protection of the VDR against proteolytic degradation. In conclusion, the altered VDR stability and the possibly underlying change in VDR conformation caused by KH1060 could be an explanation for its enhanced bioactivity.

Full text

PDF
10685

Images in this article

10687Fig. 3
on p.10687
10688Fig. 4
on p.10688
10688Fig. 5
on p.10688
10689Fig. 7
on p.10689

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe J., Takita Y., Nakano T., Miyaura C., Suda T., Nishii Y. A synthetic analogue of vitamin D3, 22-oxa-1 alpha,25-dihydroxyvitamin D3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology. 1989 May;124(5):2645–2647. doi: 10.1210/endo-124-5-2645. [DOI] [PubMed] [Google Scholar]
  2. Allan G. F., Leng X., Tsai S. Y., Weigel N. L., Edwards D. P., Tsai M. J., O'Malley B. W. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem. 1992 Sep 25;267(27):19513–19520. [PubMed] [Google Scholar]
  3. Arbour N. C., Prahl J. M., DeLuca H. F. Stabilization of the vitamin D receptor in rat osteosarcoma cells through the action of 1,25-dihydroxyvitamin D3. Mol Endocrinol. 1993 Oct;7(10):1307–1312. doi: 10.1210/mend.7.10.8264662. [DOI] [PubMed] [Google Scholar]
  4. Baker A. R., McDonnell D. P., Hughes M., Crisp T. M., Mangelsdorf D. J., Haussler M. R., Pike J. W., Shine J., O'Malley B. W. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A. 1988 May;85(10):3294–3298. doi: 10.1073/pnas.85.10.3294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beekman J. M., Allan G. F., Tsai S. Y., Tsai M. J., O'Malley B. W. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol. 1993 Oct;7(10):1266–1274. doi: 10.1210/mend.7.10.8264659. [DOI] [PubMed] [Google Scholar]
  6. Bikle D. D. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev. 1992 Nov;13(4):765–784. doi: 10.1210/edrv-13-4-765. [DOI] [PubMed] [Google Scholar]
  7. Binderup L., Latini S., Binderup E., Bretting C., Calverley M., Hansen K. 20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol. 1991 Sep 27;42(8):1569–1575. doi: 10.1016/0006-2952(91)90426-6. [DOI] [PubMed] [Google Scholar]
  8. Bouillon R., Okamura W. H., Norman A. W. Structure-function relationships in the vitamin D endocrine system. Endocr Rev. 1995 Apr;16(2):200–257. doi: 10.1210/edrv-16-2-200. [DOI] [PubMed] [Google Scholar]
  9. Brown A. J., Finch J., Grieff M., Ritter C., Kubodera N., Nishii Y., Slatopolsky E. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology. 1993 Sep;133(3):1158–1164. doi: 10.1210/endo.133.3.8396012. [DOI] [PubMed] [Google Scholar]
  10. Brown G., Bunce C. M., Rowlands D. C., Williams G. R. All-trans retinoic acid and 1 alpha,25-dihydroxyvitamin D3 co-operate to promote differentiation of the human promyeloid leukemia cell line HL60 to monocytes. Leukemia. 1994 May;8(5):806–815. [PubMed] [Google Scholar]
  11. Brown T. A., DeLuca H. F. Sites of phosphorylation and photoaffinity labeling of the 1,25-dihydroxyvitamin D3 receptor. Arch Biochem Biophys. 1991 May 1;286(2):466–472. doi: 10.1016/0003-9861(91)90067-s. [DOI] [PubMed] [Google Scholar]
  12. Costa E. M., Feldman D. Measurement of 1,25-dihydroxyvitamin D3 receptor turnover by dense amino acid labeling: changes during receptor up-regulation by vitamin D metabolites. Endocrinology. 1987 Mar;120(3):1173–1178. doi: 10.1210/endo-120-3-1173. [DOI] [PubMed] [Google Scholar]
  13. Dame M. C., Pierce E. A., Prahl J. M., Hayes C. E., DeLuca H. F. Monoclonal antibodies to the porcine intestinal receptor for 1,25-dihydroxyvitamin D3: interaction with distinct receptor domains. Biochemistry. 1986 Aug 12;25(16):4523–4534. doi: 10.1021/bi00364a011. [DOI] [PubMed] [Google Scholar]
  14. Dilworth F. J., Calverley M. J., Makin H. L., Jones G. Increased biological activity of 20-epi-1,25-dihydroxyvitamin D3 is due to reduced catabolism and altered protein binding. Biochem Pharmacol. 1994 Mar 15;47(6):987–993. doi: 10.1016/0006-2952(94)90409-x. [DOI] [PubMed] [Google Scholar]
  15. Dusso A. S., Negrea L., Gunawardhana S., Lopez-Hilker S., Finch J., Mori T., Nishii Y., Slatopolsky E., Brown A. J. On the mechanisms for the selective action of vitamin D analogs. Endocrinology. 1991 Apr;128(4):1687–1692. doi: 10.1210/endo-128-4-1687. [DOI] [PubMed] [Google Scholar]
  16. Eisman J. A., Barkla D. H., Tutton P. J. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res. 1987 Jan 1;47(1):21–25. [PubMed] [Google Scholar]
  17. Elstner E., Lee Y. Y., Hashiya M., Pakkala S., Binderup L., Norman A. W., Okamura W. H., Koeffler H. P. 1 alpha,25-Dihydroxy-20-epi-vitamin D3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood. 1994 Sep 15;84(6):1960–1967. [PubMed] [Google Scholar]
  18. Keidel S., LeMotte P., Apfel C. Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping. Mol Cell Biol. 1994 Jan;14(1):287–298. doi: 10.1128/mcb.14.1.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Leng X., Tsai S. Y., O'Malley B. W., Tsai M. J. Ligand-dependent conformational changes in thyroid hormone and retinoic acid receptors are potentially enhanced by heterodimerization with retinoic X receptor. J Steroid Biochem Mol Biol. 1993 Dec;46(6):643–661. doi: 10.1016/0960-0760(93)90306-h. [DOI] [PubMed] [Google Scholar]
  20. Mathieu C., Waer M., Casteels K., Laureys J., Bouillon R. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology. 1995 Mar;136(3):866–872. doi: 10.1210/endo.136.3.7867594. [DOI] [PubMed] [Google Scholar]
  21. Nayeri S., Danielsson C., Kahlen J. P., Schräder M., Mathiasen I. S., Binderup L., Carlberg C. The anti-proliferative effect of vitamin D3 analogues is not mediated by inhibition of the AP-1 pathway, but may be related to promoter selectivity. Oncogene. 1995 Nov 2;11(9):1853–1858. [PubMed] [Google Scholar]
  22. Peleg S., Sastry M., Collins E. D., Bishop J. E., Norman A. W. Distinct conformational changes induced by 20-epi analogues of 1 alpha,25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor. J Biol Chem. 1995 May 5;270(18):10551–10558. doi: 10.1074/jbc.270.18.10551. [DOI] [PubMed] [Google Scholar]
  23. Pernalete N., Mori T., Nishii Y., Slatopolsky E., Brown A. J. The activity of 22-oxacalcitriol in osteoblast-like (ROS 17/2.8) cells. Endocrinology. 1991 Aug;129(2):778–784. doi: 10.1210/endo-129-2-778. [DOI] [PubMed] [Google Scholar]
  24. Reichel H., Koeffler H. P., Norman A. W. The role of the vitamin D endocrine system in health and disease. N Engl J Med. 1989 Apr 13;320(15):980–991. doi: 10.1056/NEJM198904133201506. [DOI] [PubMed] [Google Scholar]
  25. Sandgren M. E., Deluca H. F. An immunoradiometric assay for 1,25-dihydroxyvitamin D3 receptor. Anal Biochem. 1989 Nov 15;183(1):57–63. doi: 10.1016/0003-2697(89)90171-1. [DOI] [PubMed] [Google Scholar]
  26. Sasaki H., Harada H., Handa Y., Morino H., Suzawa M., Shimpo E., Katsumata T., Masuhiro Y., Matsuda K., Ebihara K. Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression. Biochemistry. 1995 Jan 10;34(1):370–377. doi: 10.1021/bi00001a045. [DOI] [PubMed] [Google Scholar]
  27. Simons S. S., Jr, Sistare F. D., Chakraborti P. K. Steroid binding activity is retained in a 16-kDa fragment of the steroid binding domain of rat glucocorticoid receptors. J Biol Chem. 1989 Aug 25;264(24):14493–14497. [PubMed] [Google Scholar]
  28. Veyron P., Pamphile R., Binderup L., Touraine J. L. Two novel vitamin D analogues, KH 1060 and CB 966, prolong skin allograft survival in mice. Transpl Immunol. 1993;1(1):72–76. doi: 10.1016/0966-3274(93)90062-d. [DOI] [PubMed] [Google Scholar]
  29. Vink-van Wijngaarden T., Pols H. A., Buurman C. J., van den Bemd G. J., Dorssers L. C., Birkenhäger J. C., van Leeuwen J. P. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res. 1994 Nov 1;54(21):5711–5717. [PubMed] [Google Scholar]
  30. Wiberg K., Ljunghall S., Binderup L., Ljunggren O. Studies on two new vitamin D analogs, EB 1089 and KH 1060: effects on bone resorption and osteoclast recruitment in vitro. Bone. 1995 Oct;17(4):391–395. doi: 10.1016/s8756-3282(95)00246-4. [DOI] [PubMed] [Google Scholar]
  31. Wiese R. J., Uhland-Smith A., Ross T. K., Prahl J. M., DeLuca H. F. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem. 1992 Oct 5;267(28):20082–20086. [PubMed] [Google Scholar]
  32. van den Bemd G. J., Pols H. A., Birkenhäger J. C., Kleinekoort W. M., van Leeuwen J. P. Differential effects of 1,25-dihydroxyvitamin D3-analogs on osteoblast-like cells and on in vitro bone resorption. J Steroid Biochem Mol Biol. 1995 Dec;55(3-4):337–346. doi: 10.1016/0960-0760(95)00218-9. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES